Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 13/20 | 0.43 |
| ▸ | RARG | P13631 | 6/20 | 0.40 |
| ▸ | RARB | P10826 | 5/20 | 0.40 |
| ▸ | RARA | P10276 | 5/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.35 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 4/20 | 0.34 |
| ▸ | RXRG | P48443 | 4/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16731567 | 0.86 | RXRA (0.40) | RXRARARGRARBRARACYP26A1 | |
| SCHEMBL7931914 | 0.78 | RXRA (0.49) | RXRARARGRARBRARACYP26A1 | |
| SCHEMBL3550442 | 0.78 | RXRA (0.41) | RXRARARGRARBRARACYP26A1 | |
| SCHEMBL24809295 | 0.74 | RXRA (0.42) | RXRARARGRARBRARARXRB | |
| SCHEMBL4666966 | 0.71 | RXRA (0.44) | RXRARARGRARBRARACYP26A1 | |
| SCHEMBL18226969 | 0.71 | DPP4 (0.39) | — | |
| SCHEMBL7138144 | 0.70 | RXRA (0.42) | RXRA | |
| SCHEMBL17283110 | 0.69 | RXRA (0.38) | RXRARARGRARBRARACYP26A1 | |
| SCHEMBL11599145 | 0.68 | RXRA (0.42) | RXRARARGRARBRARACYP26A1 | |
| SCHEMBL1616186 | 0.67 | RXRA (0.53) | RXRARARGRARBRARACYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1324970-B1 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | HOFFMANN LA ROCHE (CH) | 2008-11-05 | — | — | EP | disclosed |
| EP-1935869-A1 | Retinoids for the treatment of emphysema | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| US-6777418-B2 | FOR TREATING OR PREVENTING EMPHYSEMA, CANCER AND DERMATOLOGICAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-08-17 | — | — | US | disclosed |
| EP-1324970-A2 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-09 | — | — | EP | disclosed |
| US-20020082265-A1 | For treating or preventing emphysema, cancer and dermatological disorders | SYNTEX (U.S.A.) LLC | 2002-06-27 | — | — | US | disclosed |
| WO-2002028810-A2 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082265-A1 | For treating or preventing emphysema, cancer and dermatological disorders | RXRA, RXRG, RXRB | RXRA 1/4885RARG 4/4885RARB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.